Full-Time

Vice President

Regulatory, 24002-B-615-MED

Confirmed live in the last 24 hours

ArsenalBio

ArsenalBio

201-500 employees

Develops programmable cell therapies for cancer

Biotechnology
Healthcare

Compensation Overview

$285.7k - $350kAnnually

Senior, Expert

Remote in USA

Remote work based in South San Francisco office.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • A minimum of a Bachelor's and or undergraduate degree in biological, pharmaceutical, chemical or engineering sciences is required.
  • 15+ years of experience, at least 10+ years in regulatory affairs, inclusive of postgraduate education and/or Advanced scientific degree preferred in the sciences, or health-related field
  • Knowledge of EU and FDA regulations is required.
  • Experience in filing regulatory submissions from early development to pre and post-approval submissions and product lifecycle management in the area of Cell Therapy
  • Strong knowledge of eCTD elements and structure and regulatory writing skills
  • Demonstrated knowledge of regulatory requirements in the design and conduct of clinical trials, including preparation of regulatory submissions
  • Experience with regulations or product development in gene therapy, such as CAR-Ts, AAVs, or CRISPR technology etc. is highly preferred
  • Demonstrated enterprise leadership skills and ability to build an experienced regulatory affairs team
  • Ability to work in a fast-paced, start-up environment
  • Experience directly writing submission documents that support clinical trials, marketing applications, and lifecycle management is highly preferred
  • Strong attention to detail with the ability to multi-task and handle multiple responsibilities simultaneously
  • Excellent organizational skills and an ability to prioritize effectively to deliver results within reasonably established timelines
  • Effective and efficient written and oral communication skills
  • Candidates must be authorized to work in the U.S
  • Ability to work independently and as part of a team
Responsibilities
  • Lead program teams in preparing regulatory submissions including briefing documents, INTERACT/IND/CTA/BLA filings, and marketing applications
  • Oversee preparation of responses to all regulatory authority queries
  • Plan and lead meetings with regulatory authorities, including end-of-phase 1/2 meetings.
  • Manage critical clinical regulatory timelines and work with team members to resolve issues related to non-clinical studies, and clinical development and work in partnership with the CMC team.
  • Serve as primary regulatory representative on assigned projects at internal meetings as well as at meetings with regulatory agencies for all clinical and CMC-related issues
  • Maintain detailed knowledge of the global regulatory environment relevant to cell therapies and regenerative medicine including accelerated review programs.
  • Communicate changing regulatory agency requirements; support pertinent regulatory intelligence per needs of programs
  • Collaborate with external consultants, clinicians, and CROs to provide regulatory guidance.

ArsenalBio focuses on developing programmable cell therapies to treat solid tumor cancers. Their approach involves reprogramming cells to enhance their ability to fight cancer. The company is currently in the clinical stage, concentrating on research and development to bring these therapies to market. Unlike many competitors, ArsenalBio emphasizes a diverse team of experts from various scientific and clinical backgrounds, which strengthens their ability to innovate in cancer treatment. The ultimate goal is to provide effective therapies for patients suffering from solid tumor cancers, thereby improving their chances of recovery.

Company Stage

Series C

Total Funding

$612.8M

Headquarters

San Francisco, California

Founded

2019

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

75%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful clinical trials, such as the ongoing Phase 1/2 trial for AB-2100, could lead to breakthrough treatments for solid tumors, significantly impacting patient outcomes.
  • The $220 million Series B financing round and partnerships with major investors like Softbank Vision Fund 2 and Bristol-Myers Squibb provide strong financial backing for continued R&D and clinical advancements.
  • Presentations at high-profile conferences like AACR highlight ArsenalBio's innovative progress and can attract further investment and collaboration opportunities.

What critics are saying

  • As a clinical stage company, ArsenalBio faces the inherent risk of clinical trial failures, which could delay or halt the commercialization of their therapies.
  • The competitive landscape in the biotechnology sector is intense, with numerous companies vying to develop effective cancer treatments, potentially impacting ArsenalBio's market share.

What makes ArsenalBio unique

  • ArsenalBio's focus on programmable cell therapies for solid tumors sets it apart from competitors who primarily target hematological malignancies.
  • The company's proprietary CITE technology and Integrated Circuit T (ICT) cell approach offer a unique method to enhance T cell functionality and overcome tumor microenvironments.
  • Strategic collaborations with industry leaders like Genentech and Thermo Fisher Scientific bolster ArsenalBio's technological capabilities and market positioning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision coverage

Virtual & telehealth options

Parental leave

Flexible work schedule

Flexible PTO

Mental health resources